Extensive experience and expertise

Our board of directors and executive management team embody our vision of building a leading renal company. These teams bring extensive pharmaceutical, biotech and renal experience and expertise. You can view the bios of the executive management team below.

  • Greg Madison, Chief Executive Officer and Board Member

    Greg Madison has served as the Company’s Chief Executive Officer since April 30, 2015, previously serving as its President and Chief Operating Officer. Mr. Madison joined Keryx in February 2014 from AMAG Pharmaceuticals (AMAG), where he served as the Executive Vice President and Chief Commercial Officer and in 2013 led the team to significant growth in net revenues. Prior to AMAG, Mr. Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division. In this role, Mr. Madison led a global organization with three marketed products with combined revenues exceeding $1 billion. 
Mr. Madison’s prior experience in the Renal division included serving as Vice President and General Manager of the U.S. business; Vice President of U.S. sales; and Vice President of U.S. marketing where he led all pre-launch preparation for Renvela®, now the leading phosphate binder in the U.S. market.

    During his tenure with Genzyme, Mr. Madison also had roles in sales management, training, managed markets and reimbursement. Prior to joining Genzyme, Mr. Madison spent five years at Janssen Pharmaceuticals in sales and sales management roles, and began his career in the pharmaceutical industry in sales with 
Wyeth-Ayerst. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst.

  • Brian R. Adams, SVP, General Counsel & Secretary

    Mr. Adams joined Keryx in 2014, bringing significant legal and business management experience within the pharmaceutical industry to the Company. As Keryx’s General Counsel, he oversees all legal, compliance and intellectual property matters. He also holds responsibility for the core function, information technology.

    Mr. Adams joined the Company from Algeta ASA, where he served as its General Counsel, with oversight of all global legal matters, corporate governance, alliance management and strategic transactions, including the highly successful launch of of Xofigo® in prostate cancer, resulting in a $2.9B acquisition bid for Algeta by Bayer AG. Prior to joining Algeta in 2012, Mr. Adams spent six years as an in-house counsel for Genzyme Corporation and AVEO Oncology.

    Throughout his career, Mr. Adams has provided domestic and international legal support for product development, operations, commercialization, securities, healthcare compliance and licensing/M&A transactions.  Prior to joining Genzyme, Mr. Adams practiced in the Boston office of Bingham McCutchen LLP, where he advised private equity sponsors, biotech and other emerging technology companies on a broad range of corporate matters and financing transactions.  Mr. Adams received a BA from Harvard University and a law degree (JD) from the Catholic University of America’s Columbus School of Law.

  • Melissa Bradford-Klug, SVP, Chief Business Officer

    Melissa Bradford-Klug is chief business officer at Keryx and is responsible for business development, corporate strategy and alliance management. She joined Keryx in January 2017 bringing to the company more than 17 years of strategic planning, licensing and business development expertise in the life sciences industry. Prior to Keryx, Ms. Bradford-Klug was at AMAG Pharmaceuticals, from 2014 to 2016, where she served as senior vice president of business development and strategy and executed multiple transformational acquisitions that led to AMAG’s portfolio expansion into maternal and women’s health. Prior to AMAG, she spent approximately 10 years at Mallinckrodt where she was vice president, business development and licensing. During her tenure at Mallinckrodt, she completed several transformational acquisitions and divestitures and was instrumental in the spinout of Mallinckrodt from Covidien. Earlier in her career, she held leadership roles with Baxter International and Eli Lilly and Company. Ms. Bradford-Klug received an M.B.A. in Finance from DePaul University and a B.S. in chemistry from Maryville University.

  • Christine Carberry, SVP, Chief Operating Officer

    Christine Carberry joined Keryx in January 2017 as chief operating officer. She brings to the team more than 30 years of biotech and pharmaceutical leadership and excellence in technical operations and strategic plan execution. Her deep experience includes research, development and lifecycle management for commercial medicines and building a pipeline through the assessment and integration of assets. Prior to Keryx, Ms. Carberry was an executive team member and senior vice president, quality, technical operations, program and alliance management at FORUM Pharmaceuticals. Prior to FORUM, Ms. Carberry spent 25 years at Biogen and held roles of increasing responsibility, culminating as vice president, program and alliance management. Ms. Carberry has an M.S. in Innovation and Technology Management from Boston University, has attended executive leadership and strategic management courses at Harvard University, and is a certified strategic alliance professional (CSAP). She has a B.S. in Biochemistry from University of New Hampshire.

  • Scott Holmes, SVP, Chief Financial Officer

    Mr. Holmes joined Keryx in July 2015 bringing nearly 20 years of life sciences and financial management expertise to the Company. Mr. Holmes joined the company from AMAG Pharmaceuticals where he most recently served as senior vice president, finance and investor relations during a period of high growth driven by acquisitions and public financings. Prior to AMAG, from 2009 to 2011, he was vice president of finance and treasurer of Molecular Biometrics Inc., a commercial stage medical diagnostics company and vice president of finance & administration of On-Q-ity Inc., an oncology diagnostics company. Prior to 2009, he spent five years at Dynogen Pharmaceuticals, Inc., a privately held pharmaceutical company, where he was vice president finance & administration and treasurer. Mr. Holmes previously was a senior auditor with Ernst & Young, LLP and earned his Certified Public Accountant certificate in the Commonwealth of Massachusetts. He holds a dual M.S/M.B.A degree from Northeastern University Graduate School of Business Administration and B.A. in History from Middlebury College.

  • John F. Neylan, MD, SVP, Chief Medical Officer

    Dr. Neylan, an accomplished nephrologist, transplantation specialist, and biopharmaceutical executive, joined the Company in April 2015 as Chief Medical Officer. Dr. Neylan brings to Keryx broad-based experience in all phases of therapeutic development across primary care, specialty and rare disease indications.  Most recently, and since 2008, Dr. Neylan, served as Senior Vice President, Clinical Development, at Genzyme Corporation, focusing on specialty metabolic diseases.  From 2000-2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise.

    Prior to joining industry, Dr. Neylan held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at UC Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan received his BS from Duke University and his MD from Rush Medical School in Chicago.  He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women’s Hospital, Harvard University. Dr. Neylan has a proven track record for successful INDs, NDA/BLAs, and MAAs involving NCEs, polymers, biologics and RNA-based therapeutics and has authored more than 70 scientific manuscripts and book chapters.  He is Past-President of the American Society of Transplantation and past Board Member of the National Kidney Foundation, and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.

  • Amy B. Sullivan, SVP, Corporate Affairs

    Amy Sullivan joined Keryx in April 2014 and serves as our senior vice president of corporate affairs. In this role, Ms. Sullivan directs the company’s investor relations, corporate communications, internal communications and advocacy programs. Ms. Sullivan brings to Keryx more than two decades of broad corporate communications and investor relations experience in the biotech and healthcare industries, including a substantial background in creating and managing communications strategies for both development stage and commercial companies. She has also been successful in helping organizations position and differentiate themselves in competitive environments. Prior to joining Keryx, Ms. Sullivan spent five years at AMAG Pharmaceuticals where she was vice president of investor relations and corporate communications leading the company’s investor relations, public relations, and employee communications activities. She also held investor relations and communications leadership roles at Idenix Pharmaceuticals, Genencor International, Perkin Elmer and Thermo Fisher. Ms. Sullivan holds a Masters in Business Administration degree from Bentley University and a Bachelor of Science degree from Salem State University.